Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02735824 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Genetic Study of Immunodeficiency: Search for New Genetic Causes for Primary Immunodeficiencies

Study acronym: GSI
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 2 to 1v9 Show 4 more changesShow less
    • Interventions: blood sampling (Procedure), blood sampling and skin biopsy (Procedure), blood sampling or mouth swap (Procedure) to Blood Sampling (Procedure), Mouth Swab or Saliva Collection (Procedure), Skin Biopsy (Procedure)
    • Eligibility criteria expanded, about 33 words
    • Collaborators shortened, about 7 words
    • Publications: 39 to 42
  2. Primary completion date: Jan 2022 to Jul 2027
    • Study completion date: Jul 2022 to Dec 2027
    • Publications: 36 to 39
    v8
  3. Publications: 12 to 36v7
  4. Publications: 10 to 12v6
  5. Primary completion date: Jan 2019 to Jan 2022
    • Study completion date: Jul 2019 to Jul 2022
    • Collaborators: 1 to 2
    • Publications: 5 to 10
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Publications: 2 to 5
    • Collaborators expanded, about 4 words
    v4
  2. Study sites: 1 to 2
    • Publications: 1 to 2
    v3
  3. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Individuals with suspected primary immunodeficiency will be studied and the results compared with healthy controls. Primary immunodeficiency may manifest as recurrent, severe or unusual infections as well as signs and symptoms of immune dysregulation such as autoimmunity or lymphoproliferation.
Trial Details
NCT Number NCT02735824
Lead Sponsor University Children's Hospital, Zurich
Conditions
(from sponsor)		 Immunologic Deficiency Syndromes, Primary Immune Deficiency (PID)
Related terms Immunologic Deficiency Syndromes, Primary Immunodeficiency Diseases
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov